Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer
NCT01189435Phase 2Terminated
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2010
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Memorial Sloan Kettering Cancer Center. Started Aug 2010; status: terminated.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01189435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01189435.